Related content

Cytochrome P₄₅₀ 2C9 phenotyping using low-dose tolbutamide

By Jetter Alexander   Kinzig-Schippers Martina   Skott Andreas   Lazar Andreas   Tomalik-Scharte Dorota   Kirchheiner Julia   Walchner-Bonjean Monika   Hering Ursula   Jakob Verena   Rodamer Michael   Jabrane Wafaâ   Kasel Dirk   Brockmöller Jürgen   Fuhr Uwe   Sörgel Fritz  

European Journal of Clinical Pharmacology, Vol. 60, Iss. 3, 2004-05 ,pp. : 165-171

Springer Publishing Company

Access to resources Recommend Favorite

Fatal intoxication cases: cytochrome P ₄₅₀ 2D6 and 2C19 genotype distributions

By Zackrisson A.   Holmgren P.   Gladh A.   Ahlner J.   Lindblom B.  

European Journal of Clinical Pharmacology, Vol. 60, Iss. 8, 2004-10 ,pp. : 547-552

Springer Publishing Company

Access to resources Recommend Favorite

Effect of the novel anxiolytic drug deramciclane on cytochrome P ₄₅₀ 2D6 activity as measured by desipramine pharmacokinetics

By Laine Kari   Bruyn Steven   Björklund Harry   Rouru Juha   Hänninen Jutta   Scheinin Harry   Anttila Markku  

European Journal of Clinical Pharmacology, Vol. 59, Iss. 12, 2004-02 ,pp. : 893-898

Springer Publishing Company

Access to resources Recommend Favorite

Increased liability of tramadol–warfarin interaction in individuals with mutations in the cytochrome P ₄₅₀ 2D6 gene

By Hedenmalm Karin   Lindh Jonatan   Säwe Juliette   Rane Anders  

European Journal of Clinical Pharmacology, Vol. 60, Iss. 5, 2004-07 ,pp. : 369-372

Springer Publishing Company

Access to resources Recommend Favorite

Identification of cytochromes P₄₅₀ 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro

By Ufer Mike   Svensson Jan   Krausz Kristopher   Gelboin Harry   Rane Anders   Tybring Gunnel  

European Journal of Clinical Pharmacology, Vol. 60, Iss. 3, 2004-05 ,pp. : 173-182

Springer Publishing Company

Access to resources Recommend Favorite